MTG2:
Disorders of Calcium & Phosphate Homeostasis

Specific Conditions

Hypercalcemia

PTH dependant hypercalcemia or rare forms of primary hyperparathyroidism

ICD code: E21

Hyperparathyroidism is due to the excessive secretion of PTH by one or more parathyroid glands. It leads to hypercalcemia and increased excretion of calcium in the urine. Rare forms of primary hyperparathyroidism are 1-hyperparathyroidism diagnosed in children or young adults and 2-hyperparathyroidism associated with germline mutations in susceptibility genes. The symptoms are mainly related to the level of serum calcium and/or to the kidney/urinary tract complications. In addition, the features associated with the genetic defects may also lead to the diagnosis.

PTH non-dependant hypercalcemia

ICD code:E21

Hypercalcemia with low PTH is due to an excess in vitamin D action/concentration or to an increased flux of calcium from the bone (hypophosphatasia, bone resoprtion due to PTHrP or cytokines production). The symptoms are mainly related to the level of serum calcium and/or to the kidney/urinary tract complications. Hypercalcemia due to anomalies in vitamin D metabolism is mainly diagnosed in neonates and young children with severe hypercalcemia and nephrocalcinosis. Hypophosphatasia may be diagnosed because of hypercalcelmia, hyperphosphatemia, low PTH and severely impaired bone mineralization.

Parathyroid cancer

ICD code:C75.0

Parathyroid cancer usually manifests as severe hypercalcemia, i.e. anorexia, polyuria, fatigue, dehydration, bone pain, subcortical bone resorption, pathological fractures and renal complications of hypercalciuria. A mass may be palpable in the neck.

Familial Hypocalciuric Hypercalcemia (FHH)

ICD code:E83.5A

Familial hypocalciuric hypercalcemia (FHH) is a generally asymptomatic genetic disorder of phosphocalcic metabolism characterised by lifelong moderate hypercalcemia along with normo- or hypocalciuria and elevated plasma parathyroid hormone (PTH) concentration.FHH is biologically characterised by moderate but significant hypercalcemia associated with levels of PTH and urinary calcium excretion that appear inappropriate in the presence of the hypercalcemia: serum levels of PTH are, in general, normal or slightly increased and calciuria is low. FHH is usually asymptomatic but rarely symptoms of fatigue, weakness, excessive thirst and concentration problems are experienced.

Neonatal Severe Primary Hyperparathyroidism (NSHPT)

ICD code:E83.5A

Neonatal Severe Primary Hyperparathyroidism (NSHPT) is a severe and sometimes lethal disease if it is left untreated. its is characterised by severe hypercalcemia, very high levels of PTH, and bone resorption. As consequences, the neonates may present with fractures and renal insufficiency. In most cases, the parathyroidectomy of 4 glands is necessary to control the disease.

Hypocalcemia

 

 

Hypoparathyroidism

ICD code:E20

Hypoparathyroidism is due to the lack of production/secretion of PTH. It is characterised by low calcium, high phosphate and low PTH. Symptoms are mainly related to low levels of calcium can include: paresthesias, numbness, seizures and tetany (including muscle twitches and hand and foot spasms); in severe cases, hypocalcemia leads to cardiac complications. Long-term complications are frequent such as tissues calcifications, nephrocalcinosis, cognitive and neuropsychiatric difficulties. In children, hypoparathyroidism is mainly due to the impaired development of parathyroid glands; in adolescents and adults, hypoparathyroidism may be due to autimmune diseases, drug side-effects and neck surgery.

Autosomal Dominant Hypocalcemia

ICD code:E20

Autosomal dominant hypocalcemia (AD hypocalcemia) is a disorder of calcium homeostasis characterised by variable degrees of hypocalcemia with abnormally low levels of parathyroid hormone (PTH) and persistant normal or elevated calciuria. Clinical expression and age of onset are extremely variable (depending on the degree of hypocalcemia), ranging from completely asymptomatic patients to patients with limited symptoms (cramps, asthenia, paresthesias) and patients with severe symptoms (i.e. recurrent seizures) similar to that of hypoparathyroidism.

Pseudohypoparathyroidism (PHP) and related disorders

ICD code:E89.2

Pseudohypoparathyroidism (PHP) has been recently reclassified as Inactivated PTH/PTHrP Signalling Disorder (iPPSD).PHP (iPPSD) is characterised by the end-organ resistance to PTH. Patients present with hypocalcemia, hyperphosphatemia and elevated PTH in absence of vitamin D deficiency. Symptoms related to low levels of calcium can include: paresthesias, numbness, seizures and tetany (including muscle twitches and hand and foot spasms). PTH resistance develops usually during infancy, yet may be diagnosed in adults patients. In some subtypes of PTH (iPPSD), patients present with resistances to other hormones (TSH, GHRH, Calcitonin), early-onset obesity, variable degree of cognitive impairment, ectopic ossifications in cutaneous and adipose tissues and Albright Osteodystrophy (brachydactyly, stocky build and adult short stature).

Vitamin D Dependent Rickets (VDDR) type 1 and 2

ICD code:E20

Hypocalcemic vitamin D-dependent rickets (VDDR-I) is an early-onset hereditary vitamin D metabolism disorder characterised by severe hypocalcemia and hypophosphatemia leading to osteomalacia and severe rickets. The disease manifests within the first year of life with hypotonia, tetany, seizures, muscle weakness, poor growth, fractures, impaired motor development, teeth defects including enamel hypoplasia and, in some VDDR2, alopecia. The rickets is resistant to 25OHvitamin D treatment and requires an expert care.

Phosphate disturbances

Inherited and rare forms of hypophosphatemia and phosphate wasting

ICD code:E83.30

Phosphate wasting leads to hypophosphatemia hence osteomalacia, rickets, mineralization defects, bone deformities, bone pain, poor growth, anomalies of teeth mineralization and muscle function impairment. Additional features may include nephrocalcinosis, craniosynostosis, Chiari 1, hearing impairment, entesopathies and hyperparathyroidism. Hypophosphatemia associated with phosphate wasting is usually diagnosed in young children, yet the features are so variable that diagnosis may be reached only in adults or parents of affected patients. Hypophosphatemia associated with phosphate wasting is caused by genetic conditions leading to an increased production/action of the hormone FGF23. In rare cases, the low phosphate level is due to anomalies in the renal phosphate transport (genetic or aquired).

Acquired oncogenic hypophosphatemia or Tumor Induced Osteomalacia (TIO)

ICD code:E83.30

Oncogenic hypophosphatemia or Tumor Induced Osteomalacia (TIO) leads to severe hypophosphatemia and phosphate wasting due to a tumoral secretion of FGF23 by mesenchymal tumors; the calcium level is also usually low. Patients (usually adults) present with severe muscular defects, fractures, pseudofractures, bone and muscular pain. It is crucial to localize the source of FGF23 secretion through the best available imaging techniques.

Hyperphosphatemia and tumoral calcinosis

ICD code:E83.30

Hyperphosphatemia may be due to the impaired excretion of urinary phosphate. Most cases are of genetic origin and are characterised by a lack of FGF23 secretion. Patients may present with joints and bone pain, diaphysitis and often severe ectopic calcifications.

Edit.

Information video for patients and healthcare professionals

Type and Press “enter” to Search

Search
Privacy Overview
Endo-ERN

Endo-ERN Privacy Policy

Endo-ERN is committed to user’s privacy and does not track personal data when visiting our website. We act in accordance with Regulation 2016/679 of the European Parliament and of the Council.

‘Personal data’ means any information relating to an identified or identifiable natural person. An identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as:

  • a name
  • an identification number
  • location data
  • an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person

Cookies

Endo-ERN only tracks anonymised data for statistical purposes. We do this via analytical cookies, placed through an anonymous IP Google analytics tag. The purpose of these cookies are to track the efficiency and success of the website.

These cookies do not store any personal data that can be linked to a natural person, but may save data such as inter alia, data about the website from which a person has come (the so-called referrer), which sub-pages were visited, or how often and for what duration a sub-page was viewed. The data collected through this is general data only, and cannot be traced back to one person.

It is possible to prevent the setting of cookies, by means of a setting of the Internet browser used. On top of that, already set cookies may be deleted at any time via an Internet browser or other software programs. This is possible in all popular Internet browsers.

Google Analytics does not share any data with third parties.

The principles of data protection do not apply to anonymous information and because these cookies minimally impact the privacy of the user, it is not necessary to ask for permission to use these cookies.

Newsletter

You may always unsubscribe from our newsletter at any time through the unsubscribe button located in our newsletter. Endo-ERN is both the controller and responsible for processing of any data regarding the newsletter. Endo-ERN does not make use of a third party for the Newsletter service.

E-services

Endo-ERN has a contact form, which activates your email software and allows you to send a comment or question to a general email address. When you send such a message, your personal data is collected only to the extent necessary to reply. If the team responsible for the mailbox is unable to answer your question, or your questions has regards to another party, it might forward your email to another service.

If you have any questions about the processing of your email and related personal data, do not hesitate to include them in your message.

The collected personal data and all information related to the above mentioned consultation is stored on the email server of the Endo-ERN Coordinating office and potentially those who have been concerned in the correspondence in order to respond to your comment.

Newsletter Tracking

The Endo-ERN newsletter makes use of tracking in order to be able to conduct a statistical analysis of the success or failure of online marketing campaigns. Endo-ERN may see if an email containing a newsletter was opened by a user, when it was opened, and which links were opened. 
The data collected through this tracking is generated and stored by Endo-ERN and is not shared with third parties, but may be used to adapt future content of newsletters in order to better meet the interests of our subscribers.

Contact details

For any questions regarding our privacy policy, please contact the Endo-ERN coordinating office.

You have the right to be forgotten and removed completely from the Endo-ERN contact database. To request this, please contact the Endo-ERN coordinating office.

Endo-ERN Coordinating Center, Meibergdreef 9, 1105 AZ  AMSTERDAM. The Netherlands

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.